The Daily Brief

October 27, 2026

Kansas voters are backing marijuana legalization across party lines by substantial margins, according to the 2026 Kansas Speaks Survey released Monday. A Fort Hays State University poll of 603 adults found 58 percent support recreational legalization and 65 percent back medical cannabis access—including majorities of Democrats, Republicans, and independents on both measures. Support climbs to 61 percent when legalization is framed as a revenue-raising mechanism, suggesting voters see potential financial benefits. Context The findings arrive as Democratic gubernatorial candidate Cindy Holscher is making legalization a campaign centerpiece, arguing Kansas loses tax revenue while neighboring states profit from legal dispensaries just across the border.

Federal civil rights advocacy is amplifying the push for legalization at the national level. The Leadership Conference on Civil and Human Rights, representing over 240 organizations, disclosed Monday that it has lobbied the U.S. Senate in support of S. 5022, the Cannabis Administration and Opportunity Act. The bill, introduced in July by Senators Cory Booker, Chuck Schumer, and Ron Wyden, would remove marijuana entirely from the Controlled Substances Act, establish federal regulation and taxation, and fund expungement of past convictions in communities harmed by prohibition. The legislation remains in the Senate Finance Committee with no scheduled vote.

California's highest court is reshaping cannabis conviction law. An appellate court ruled last week that some felony cannabis cultivation convictions may be reduced to misdemeanors, reversing a lower court decision in People v. Baxter. The ruling determines that certain aggravated cultivation offenses—even those involving environmental harm allegations—qualify as "wobblers" that trial courts can reclassify, reflecting how legalization has changed the state's approach to historical enforcement actions.

Money Multiple states are grappling with regulatory and tax friction that threatens industry stability. Texas faces escalating litigation over its smokable hemp ban and fee increases: the Texas Hemp Constitutional Alliance and Green Nation filed suit this week claiming state health officials exceeded their authority, adding to multiple pending cases challenging the regulations. One lawsuit from four hemp retailers estimates the ban has caused 36,000 job losses and billions in industry losses. In Ohio, Vext Science sued Pierce Township, alleging that a 4.5 percent gross revenue fee on cannabis retailers constitutes illegal extortion. Michigan's Republican lieutenant gubernatorial candidate Jay DeBoyer announced plans to suspend the state's 24 percent cannabis tax for 12 months to provide business relief.

Rhode Island's hemp sector faces a December 11 federal deadline that leaves operators in limbo. The state's Cannabis Control Commission issued guidance allowing hemp businesses to quarantine inventory exceeding the new federal 0.4 milligram THC potency limit—but not sell it—if Congress doesn't reverse course before the deadline. The policy avoids forced destruction amid regulatory uncertainty, though operators like Lovewell Farms say the outcome remains contradictory: they can legally grow but cannot legally distribute their harvest.

Notable California courts are creating pathways for conviction relief while federal advocates push comprehensive reform. The combination of state judicial recalibration and organized civil rights pressure reflects how cannabis policy is shifting from pure prohibition toward systems that account for legalization's legal reality—and the documented harm caused by decades of enforcement against a substance now widely recognized as having medical value and generating significant tax revenue.

October 27, 2026

Grön is accelerating its nationwide footprint with today's announcement that the cannabis edibles brand has officially launched its Pearls product line in Massachusetts, New Mexico and Washington, marking the third major expansion wave in 2026. The move follows the company's entry into four additional states in early September and comes on the heels of what the company calls its largest-ever Halloween limited-edition release—the tarot-themed Grön Arcana, which outsold any previous Grön LTO in company history. Money Since parent company Wyld acquired Grön in December 2025, the brand has leveraged its parent's production-to-distribution model to fuel exponential sales growth and market penetration across previously untapped regions. The Pearls line, which differentiates itself through innovative THC-to-cannabinoid ratios including CBC, CBD, CBG and CBN, will hit dispensary shelves immediately across all three states.

Meanwhile, the global medical cannabis market is on track for transformative growth, with projections from The Business Research Company showing the industry reaching $106.5 billion by 2030—more than doubling from the current $39.52 billion in 2025. Notable The forecasted 22% compound annual growth rate through 2030 is being driven by expanding medical legalization, growing patient demand, increased scientific research, and improvements in extraction and formulation technologies. North America currently holds the largest share of the global market, while the Asia-Pacific region is projected to experience the fastest growth in the coming years. The market analysis identifies major operators including Curaleaf, Trulieve, Green Thumb Industries, Cresco Labs, Tilray, Canopy Growth, and Aurora Cannabis as key players in this expanding sector.

Puerto Rico—home to more than 250 active cannabis dispensaries and $180 million to $240 million in annual medical cannabis sales—is positioning itself as Latin America's dominant legal cannabis market. The island will host its first High Times Medical Cannabis Cup on December 5 in Old San Juan, featuring performances by Farruko, Jon Z, and Fab 5 Freddy, alongside the Cannabiz Awards. Context Puerto Rico's 75-year history as a pharmaceutical manufacturing hub has shaped a medical cannabis industry built on precise formulations, consistent dosing, and genetics developed specifically for patient needs—a foundation that positions the island favorably as federal rescheduling opens doors to expanded clinical research and international collaboration.

On the labor front, 21 workers at Greenlight Marijuana Dispensary in Joplin, Missouri voted to unionize under UFCW Local 2, citing demands for better job security, consistent scheduling, equitable tip distribution, improved wages, and protection from unilateral corporate changes. The vote reflects broader organizing momentum in Missouri's cannabis sector, where workers at High Profile Cannabis Dispensary in Columbia, Key Dispensary in Springfield, and CBD Kraton—which operates 16 stores across the state—have all voted to join UFCW unions and ratified historic first contracts over the summer. The Joplin action follows allegations last month that a dozen employees at a Springfield Greenlight location were terminated for attempting to unionize, though company representatives claimed the terminations were related to on-the-job cannabis consumption.

In California, data from 1,653 active retail licenses reveals that social equity cannabis holders are outpacing their nonequity counterparts in operational success: 81% of social equity-licensed retailers are active, compared to 76% for nonequity licenses. Money The metric signals that social equity licensing frameworks—designed to center communities disproportionately affected by cannabis prohibition—are delivering measurable economic outcomes and business stability. Separately, Safe Harbor Financial has signed a non-binding term sheet to combine with Opifex Media, creating a Nasdaq-listed diversified holding company that would operate Opifex's creator-economy platform alongside Safe Harbor's established cannabis financial services business. The combination reflects growing financial infrastructure maturation in the cannabis sector as banking and payment solutions become central to industry scaling.

October 27, 2026

Researchers Convert Hemp Waste Into Biodegradable Stem Cell Materials

Notable Scientists affiliated with universities in Spain and Ecuador have successfully transformed discarded hemp stems into hydrogels that support human stem cell growth, potentially opening new applications for industrial hemp in regenerative medicine, tissue engineering, and wound care. Published October 27 in *Discover Materials*, the study found that hemp-derived hydrogels achieved approximately 90% cell viability by day three of testing with adult human bone marrow-derived mesenchymal stem cells. The materials demonstrated a highly porous structure—approximately 78% porosity with more than 99% of pores interconnected—and absorbed roughly six times their dry weight in fluid after three hours, stabilizing at around 650% swelling capacity after 96 hours. While orange peel-derived hydrogels outperformed the hemp materials in some measures, researchers identified practical applications for both in wound dressings and tissue scaffolding, where their fluid absorption and cellular compatibility could prove valuable.

Meanwhile, the global cannabis industry faces sharply divergent regulatory directions. Brazil just crossed one million medical cannabis patients as of June 2026, and Latin America's largest cannabis fair, ExpoCannabis Brasil, expands its November 20–22 event to focus on hemp cultivation, industrial applications, and downstream industries—from construction materials to biotech and food. The expansion reflects Brazil's regulatory shift: after its Superior Court of Justice ordered the federal government and health regulator Anvisa to regulate hemp cultivation for medical and industrial use, Anvisa opened frameworks for controlled cultivation of plants with up to 0.3% THC and expanded research permissions. Market research firm Kaya Mind estimates the broader hemp market could reach R$51 billion annually under wider regulation, and the fair's program now includes agribusiness, hempcrete demonstrations, and institutional participation from Embrapa, Brazil's public agricultural research agency.

Uruguay, which legalized cannabis in 2013, takes a similar long-view approach at its 13th ExpoCannabis Uruguay fair on December 5–6, where sessions will address both neuroscience—cannabidiol's neuroprotective properties and cannabis in pediatric neurodevelopmental disorders—and the unsexy but critical business of club operations: payroll, taxes, and registration. Cait Curley, an industrial hemp expert from the U.S., will lead a live hempcrete demonstration, while Rosina Yemini will walk club operators through labor, tax, and administrative obligations including civil association registration with Uruguay's tax authority.

Money The contrast sharpens in the United States, where federal hemp-derived THC products face an existential regulatory threat. Articles from October 26–27 reference uncertainty for Minnesota breweries incorporating hemp THC, a federal hemp ban looming over the industry, and the beverage sector confronting what sources describe as an "existential threat." Brands are reportedly saying goodbye before a ban takes effect, and a backer of hemp regulation is now looking to reconciliation process as a potential legislative path forward. Willie Nelson's $200 million THC drinks brand and other companies have taken the extraordinary step of sending THC drinks to Congress to advocate for hemp regulation rather than prohibition.

Context The gap between regulatory frameworks reflects a broader pattern: countries developing hemp as an agricultural and industrial crop—with defined cultivation standards and medical applications—while the U.S. federal government weighs eliminating the legal market entirely, despite robust consumer adoption and zero recorded deaths from hemp-derived cannabinoids in human history.

October 27, 2026

Researchers at the University of Mississippi have developed a dissolving microneedle system that delivers cannabidiol (CBD) with remarkable efficiency, releasing approximately 70% of the cannabinoid within two hours in laboratory testing. Presented October 27 at the American Association of Pharmaceutical Scientists' PharmSci 360 conference, the technology addresses a persistent challenge in cannabis medicine: CBD's poor water solubility and extensive liver metabolism when taken orally. Notable The team created the microneedles using a solvent-free manufacturing process—heating at 120 degrees Celsius for just 15 minutes—that achieved 100.5% of the target drug loading while preserving the CBD in an amorphous form that enhances dissolution. The approach potentially allows CBD to bypass the digestive system entirely, opening pathways for more consistent and predictable cannabinoid delivery in future treatments.

Meanwhile, a two-year study published October 26 in Neuropsychopharmacology Reports demonstrates that medical cannabis produces sustained improvements in sleep quality among insomnia patients in the United Kingdom. Researchers from Imperial College London, King's College London, and Curaleaf Clinic tracked 211 patients enrolled in the UK Medical Cannabis Registry, measuring sleep quality on a standardized 10-point scale. Average sleep scores jumped from 2.46 before treatment to 5.79 after one month, reached 6.23 at 12 months, and remained significantly elevated at 5.14 after two years—with improvements statistically significant at every follow-up point. Patients with the most severe baseline sleep difficulties showed the strongest response: those with the lowest possible baseline score had approximately 15 times greater odds of clinically meaningful improvement compared with those whose initial scores were between four and 10. The study also found that patients receiving dried flower had nearly five times greater odds of sleep improvement compared with those receiving oil alone, and documented secondary anxiety improvements in nearly 49% of participants, with average anxiety scores declining from 10.41 to 7.36 over 24 months.

Preclinical research also suggests CBD may hold promise against chemotherapy-resistant cancers. A study detailed on Bioengineer.org found that cannabidiol selectively kills cisplatin-resistant head and neck cancer cells, potentially enhancing the effects of existing chemotherapy in cases where tumors have developed drug resistance. Context These developments arrive as cannabis science continues expanding into delivery systems, long-term outcome tracking, and oncology—domains traditionally dominated by pharmaceutical compounds with substantially higher documented risks. The adverse event rate in the UK sleep study was approximately 8%, with no life-threatening events recorded; the most common reports were insomnia, fatigue, and dry mouth. The University of Mississippi microneedle research remains preliminary and requires human and animal testing before clinical application, but the manufacturing consistency and dissolution profile suggest a viable pathway forward for cannabinoid-based pharmaceutical development.